

Evaluation/Claim Form

Must be signed by prescribing physician

Today's Date:			
Prescribing Physician's Name:			
Prescribing Physician's Address:			
	City:	Province:	Postal Code:
Patient's Name:			
Fracture Diagnosis:			
Date of EXOGEN Prescription:			
EXOGEN Serial Number: (Back of Device)			
Additional Information:			
I confirm that I have been treating the above patient for a fracture which showed no visibly progressive signs of healing. I prescribed the EXOGEN Ultrasound Bone Healing System for this patient and confirm that there was no progression to bony union measured by written evaluation of x-rays taken prior to the patient's fitting of EXOGEN ultrasound and at least 120 days (or more) after first use. See reverse side for program criteria.			
Must be signed by prescribing physician			
Print Name:			
Signature: Please print your name and sign the document			

Please complete, sign and return this form to:

Bioventus Canada ULC 2425 Matheson Blvd. East 8th Floor Mississauga, ON L4W 5K4 Customer Care: customercare-international@bioventusglobal.com T 1-855-771-0606 F 1-866-739-6436







The EXOGEN Performance Program is a Bioventus program that refunds patients their out-of-pocket payment for EXOGEN if progression of healing is not shown per criteria below. It is also designed to help reinforce patients' adherence to the prescribed treatment.

Criteria

All patients who have purchased an EXOGEN designed for the treatment of a fracture, which was prescribed by a qualified physician to treat a stable, non-displaced, established nonunion[†], delayed union or acute fracture with a fracture gap less than 10 millimeters (excluding vertebra and skull fractures) are eligible.

All patients will automatically be enrolled in the program.

Patients must treat their fracture with EXOGEN per product instructions, for a minimum of 120 days and achieve a minimum adherence of 90%.

Evaluation

Absence of healing progression (progression to bony union) is determined by the prescribing physician, comparing the patient's x-rays taken prior to using EXOGEN to one taken at 120 days or later.

The EXOGEN device contains an internal patient usage monitor that records the date, time and duration of each treatment session. This monitor will be used by Bioventus to confirm that at least 90% treatment adherence is met.

Bioventus reserves the right to amend or cancel the program at any time.

Exclusions

- Fracture types:
 - Unstable
 - Displaced
 - Greater than 10-millimeter fracture gap
 - Vertebra and skull
 - Pathological
- · Modified or altered devices
- Patient treated with EXOGEN 4000+ model
- The Performance Program is void if alternative interventions occur during the 120-day treatment period. If alternative intervention is needed, a new 120-day treatment period begins.
- EXOGEN must be purchased and received by the patient directly from Bioventus
- The EXOGEN Performance Program applies only to patients for whom the device was prescribed
- Any other costs associated with the purchase only the patient's out-of-pocket payment to Bioventus will be refunded
- · Valid only in Canada

Claims

Patients may contact a Customer Care Representative at 1-855-771-0606 for assistance. All claims must be accompanied by the following:

- Prescribing physician's assessment: completion of the Evaluation Form
- 2. Letter from the patient requesting a refund (including name, address and payment method)
- 3. Prescribed EXOGEN device returned to Bioventus

Claims must be received by Bioventus within one year of first EXOGEN treatment date.

Summary of Indications for Use: EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of osseous defects (excluding vertebra and skull) including:

- Treatment of delayed union and nonunion[†]
- Accelerating the time to heal of fresh fractures
- Treatment of stress fractures
- Accelerating repair following osteotomy
- Accelerating repair in bone transport procedures
- Accelerating repair in distraction osteogenesis procedures
- Treatment of joint fusion

[†] A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing.

There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling at www.exogen.com.

www.BioventusGlobal.com

T: 1-855-771-0606 (toll free)

E: customercare-international@bioventusglobal.com

